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Variability in low-density lipoprotein cholesterol (LDL-C) response to statins is underappreci-
ated. We characterised patients by their statin response (SR), baseline risk of cardiovascu-
lar disease (CVD) and 10-year CVD outcomes.
Methods and results
A multivariable model was developed using 183,213 United Kingdom (UK) patients without
CVD to predict probability of sub-optimal SR, defined by guidelines as <40% reduction in
LDL-C. We externally validated the model in a Hong Kong (HK) cohort (n = 170,904).
Patients were stratified into four groups by predicted SR and 10-year CVD risk score: [SR1]
optimal SR & low risk; [SR2] sub-optimal SR & low risk; [SR3] optimal SR & high risk; [SR4]
sub-optimal SR & high risk; and 10-year hazard ratios (HR) determined for first major
adverse cardiovascular event (MACE). Our SR model included 12 characteristics, with an
area under the curve of 0.70 (95% confidence interval [CI] 0.70–0.71; UK) and 0.68 (95% CI
0.67–0.68; HK). HRs for MACE in predicted sub-optimal SR with low CVD risk groups (SR2
to SR1) were 1.39 (95% CI 1.35–1.43, p<0.001; UK) and 1.14 (95% CI 1.11–1.17, p<0.001;
HK). In both cohorts, patients with predicted sub-optimal SR with high CVD risk (SR4 to
SR3) had elevated risk of MACE (UK HR 1.36, 95% CI 1.32–1.40, p<0.001: HK HR 1.25,
95% CI 1.21–1.28, p<0.001).
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Conclusions
Patients with sub-optimal response to statins experienced significantly more MACE, regard-
less of baseline CVD risk. To enhance cholesterol management for primary prevention,
statin response should be considered alongside risk assessment.
Introduction
Cardiovascular disease (CVD) is a significant cause of mortality and morbidity, accounting for
almost a third of all deaths globally [1]. Statins, the most widely prescribed class of drug world-
wide, are an effective and low-cost solution in lowering cholesterol levels and reducing future risk
of CVD [2]. Statin use is set to rise further in many countries as guidelines recommend their use
in greater proportions of the population [3, 4]. In the United States alone, the proportion of adults
whom statins are indicated has increased from 17.9% (21.8 million) to 27.8% (39.2 million) from
2002 to 2013 [5], with similar magnitude increases in most European [6] and Asian countries [7].
Following meta-analyses of cholesterol treatment trials [8, 9], the safety and intended per-
centage reductions in LDL-C achieved by specific statins (and their doses) have been well-
established. Guidelines in the United States (US), United Kingdom (UK), Europe (EU) and
Hong Kong (HK) recommend intended LDL-C reduction targets for statin therapy to reduce
CVD. The 2013 American College of Cardiology/American Heart Association (ACC/AHA)
guideline suggests a fixed dose (or intensity) of statin depending on absolute CVD risk, with
intended LDL-C reduction of 30–50% [4]. The UK National Institute of Clinical Excellence
(NICE) Guideline aims for a greater than 40% reduction in non-high-density lipoprotein cho-
lesterol (non-HDL-C) [3]. An LDL-C reduction of 50% is recommended by European Society
of Cardiology guidelines [10]. Hong Kong primary prevention guidelines follow similar ACC/
AHA, NICE, and ESC guideline targets for LDL-C reduction [11].
These guidelines are designed to curb CVD deaths; however, recent evidence has shown
that over 50% of a cohort of 165,411 patients prescribed statins for primary prevention in the
UK fail to reach treatment targets, which significantly increases risk of heart disease and stroke
[12]. The reasons are varied, but there is evidence to suggest individual variability in LDL-C
response [13] and significant non-adherence [14]. It is unclear which patient characteristics
may be associated with variation in LDL-C reduction after commencing statin therapy for pri-
mary prevention of CVD and if these clinical characteristics can be used to predict an individ-
ual’s likelihood of achieving recommended LDL-C targets. There are currently no
management strategies in clinical practice to determine if patients will experience sub-optimal
reduction in LDL-C when prescribed statins, nor the impact this may have on future CVD out-
comes. First, we conducted an international study using two large geographically distinct
cohorts to characterise LDL-C response to statin therapy in relation to baseline cardiovascular




This study used the anonymized electronic health records from the UK Clinical Practice
Research Datalink (CPRD) and the Hong Kong (HK) Clinical Data Analysis and Reporting
System (CDARS).
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CPRD contains anonymized patient data for more than 15 million patients and is represen-
tative of the general UK population [15]. CPRD is one of the largest quality-assured databases
of longitudinal medical records from primary care in the world, with over 800 UK primary
medical care practices. Regulatory approval for this study (protocol number: 17_200RA) was
obtained from the CPRD Independent Scientific Advisory Committee.
The CDARS contains data from the Hong Kong Hospital Authority, which serves a popula-
tion of over 7.4 million through 43 hospitals and institutions, 48 specialist outpatient clinics,
73 general outpatient clinics, covering approximately 80% of all hospital admissions in Hong
Kong [16]. The use of CDARS data for this study was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (protocol
number: UW 17–135).
Study population
The study cohorts comprised 183,213 patients initiating statin therapy with repeat prescrip-
tions between 3rd September 1990 and 7th June 2016 in UK CPRD and 170,904 patients
between 1st of January 2003 and 31st of December 2011 in HK CDARS. Patients were eligible
for inclusion if they were registered with their health care provider for at least 12 months.
Patients were required to have at least two recorded LDL-C measurements (directly mea-
sured). The baseline LDL measure was within 12 months before or at the initiation of statins
and the follow-up measure was within 24 months after initiation of statins. Patients on statin
treatment for primary prevention of CVD who failed to achieve greater than 40% reduction in
their untreated baseline LDL-C, recorded within the first 24 months, were defined as sub-opti-
mal LDL-C responders. This was based on the lower bound expected reduction of LDL-C rec-
ommended in CVD prevention guidelines [3, 10, 11, 17] and also recognised in meta-analyses
[8]. Percentage LDL-C reduction, which considers individual baseline levels, has been shown
to have better prognostic value than attained LDL-C for future CVD events [18]. For on-treat-
ment response, the most recent LDL-C record at or closest to 24 months was used. This was
because many routine annual medication reviews or cholesterol assessments in clinical prac-
tice are unlikely to be documented in the EHRs until beyond 12 months.
All individuals with a diagnosis of CVD (defined as coronary heart disease, cerebrovascular
disease and peripheral arterial disease) before initiating statin therapy were excluded. Candi-
date predictors (documented in S1 Table) were assessed for inclusion by clinical review and
prior evidence.
Outcomes
The primary outcome for this analysis was the incidence of first major adverse cardiovascular
event (MACE) over 10-year follow-up after initiation of statins. We defined MACE as a com-
posite of coronary heart disease (CHD), stroke, transient ischemic attack (TIA), peripheral
vascular disease (PVD), and cardiovascular (CV) death [19]. CHD included acute myocardial
infarction, coronary revascularisations, stable and unstable angina. CVD events were identi-
fied from linked primary, secondary, and death registries. These are coded diagnoses based on
National Health Service (NHS) Read codes and ICD-10 in the UK and mapped to ICD-9-CM
in HK. Secondary outcomes include all-cause mortality, and CVD outcomes by sub-type.
Study design and statistical analyses
The study involved two phases, detailed in the study flowchart (Fig 1). Phase I involved the
development and validation of the statin response (SR) propensity model and Phase II strati-
fied groups according to statin response and evaluated future CVD and mortality outcomes.
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Full methods on model development, validation, statistical methods and evaluation of future
CVD outcomes are detailed in S1 Text. Stata SE version 15 and RStudio were used for all analysis.
Results
Characteristics of the cohorts
Within 24 months following initiation of statin therapy, 51.3% of UK patients had sub-optimal
cholesterol response in the derivation cohort. However, a higher proportion of HK patients
had a sub-optimal LDL-C response (60.8%) compared to the UK. Both derivation and valida-
tion cohorts had similar mean age, mean baseline LDL-C, and proportion of females. Baseline
mean LDL-C was higher in UK patients than in HK patients (156.5 mg/dL and 156.6 mg/dL
for UK cohorts compared to 149.8 mg/dL for the HK cohort). Higher potency statins tended
to be prescribed more frequently in in the UK than in HK (with 23.6% prescribed low potency
in the UK compared to 68.5% prescribed low potency in HK). Full baseline characteristics are
presented in Table 1, with S2 Table detailing the grouping of statins based on potency.
Disease outcomes over 10-year follow-up for both cohorts are shown in Fig 2. Overall,
there were 40,928 cases of MACE (22.3%) in the UK population and 37,777 cases of MACE
Fig 1.
https://doi.org/10.1371/journal.pone.0260839.g001
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Table 1. Clinical characteristics of patients initiating statin treatment and free from cardiovascular disease at baseline (n = 183,213).
Characteristic Units UK CPRD derivation cohort UK CPRD internal validation
cohort
HK CDARS external validation
cohort
Total sample size N 128,248 54,965 170,904
Follow-up time (years) Median
(IQR)
5.29 (2.28–8.78) 5.26 (2.29–8.70) 6.92 (3.78–8.61)
Sex (Females) N (%) 60,891 (47.5) 26,161 (47.6) 89,315 (52.3)
Sub-optimal LDL-C response to statin N (%) 65,777 (51.3) 28,141 (51.2) 103,899 (60.8)
Age (years) Mean (SD) 62.9 (11.9) 62.9 (11.8) 63.0 (12.0)
Median
(IQR)
63.0 (55.0–71.0) 63.0 (55.0–71.0) 62.8 (54.7–72.0)
Baseline LDL-C (mg/dL) Mean (SD) 156.5 (44.2) 156.6 (44.2) 150.0 (41.2)
Median
(IQR)
154.7 (127.6–184.1) 154.7 (127.6–184.5) 147.6 (125.0–171.9)
Body mass index (kg/m2) Mean (SD) 28.72 (4.63) 28.70 (4.61) N/A
Median
(IQR)
28.3 (25.9–30.8) 28.25 (25.9–30.8)
Systolic blood pressure (mmHg) Mean (SD) 142 (19) 142 (19) N/A
Median
(IQR)
140 (130–150) 140 (130–150)
Diastolic blood pressure (mmHg) Mean (SD) 82 (10) 82 (10) N/A
Median
(IQR)
81 (76–88) 81 (76–88)
Ethnicity
White N (%) 11,026 (8.6) 4,738 (8.6) �
Asian 563 (0.4) 262 (0.5)
Black/African/Caribbean 448 (0.3) 180 (0.3)
Mixed/multiple 684 (0.5) 282 (0.5)
Other 380 (0.3) 163 (0.3)
Unknown 115,147 (89.8) 49,340 (89.8)
Comorbidities (prior to 1st statin)
Atrial fibrillation N (%) 4,200 (3.3) 1,821 (3.3) 3,828 (2.2)
Chronic kidney disease N (%) 3,574 (2.8) 1,592 (2.9) 3,150 (1.8)
Diabetes N (%) 20,843 (16.3) 8,928 (16.2) 32,457 (19.0)
Dyslipidaemias N (%) 10,262 (8.0) 4,375 (8.0) 10,059 (5.9)
Family history of cardiovascular
disease
N (%) 13,491 (10.5) 5,837 (10.6) N/A
Family history of hyperlipidaemia N (%) 281 (0.2) 120 (0.2) N/A
Treated hypertension N (%) 33,631 (26.2) 14,319 (26.1) 22,670 (13.3)
Hypothyroidism N (%) 5,340 (4.2) 2,243 (4.1) 2,636 (1.5)
Liver disease N (%) 1,221 (1.0) 517 (0.9) 497 (0.3)
Migraine N (%) 2,766 (2.2) 1,182 (2.2) 359 (0.2)
Nephrotic syndrome N (%) 83 (0.1) 40 (0.1) 1,062 (0.6)
Rheumatoid arthritis N (%) 1,185 (0.9) 480 (0.9) 1,377 (0.8)
Systemic lupus erythematosus N (%) 157 (0.1) 54 (0.1) 622 (0.4)
Medications (prescribed within 12 months prior to 1st statin)
Medication count Median
(IQR)
4 (1–6) 4 (1–6) 8 (5–12)
Antipsychotics N (%) 5,421 (4.2) 2,295 (4.2) 3,279 (1.9)
Other lipid lowering medication N (%) 535 (0.4) 223 (0.4) 10,885 (6.4)
Oral corticosteroids N (%) 5,390 (4.2) 2,396 (4.4) 8,906 (5.2)
(Continued)
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Table 1. (Continued)
Characteristic Units UK CPRD derivation cohort UK CPRD internal validation
cohort
HK CDARS external validation
cohort
Potency of initial statin prescribed†
Low N (%) 30,310 (23.6) 12,994 (23.6) 11,7107 (68.5)
Medium 90,514 (70.6) 38,747 (70.5) 47,825 (28.0)
High 7,424 (5.8) 3,224 (5.9) 5,972 (3.5)
Missing data
Missing body mass index N (%) 57,782 (45.1) 24,641 (44.8) N/A
Missing systolic blood pressure N (%) 15,076 (11.8) 6,354 (11.6) N/A
Missing diastolic blood pressure N (%) 15,029 (11.7) 6,337 (11.5) N/A
� According to the most recent Hong Kong population census, about 92% of its residents are Han Chinese.
† Statin potency–see S2 Table for detailed definitions.
CDARS: Clinical Data Analysis and Reporting System; CPRD: Clinical Practice Research Datalink; HK: Hong Kong; IQR: interquartile range; LDL-C: low-density
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(22.1%) in the HK population. There were some notable differences between the proportion of
stroke/TIA and CHD between cohorts, the most common MACE outcomes. There was a
higher proportion of CHD (14.9%) and PVD (2.6%) outcomes in UK patients compared to
HK patients (10.2% CHD, 0.9% PVD). There was a lower proportion of stroke/TIA (3.8%) in
UK patients compared to HK patients (8.4%). The proportion of non-CVD death in the HK
patients (13.9%) was twice that of UK patients (6.2%).
Development of sub-optimal LDL-C statin response model
The multivariable logistic model using the derivation cohort retained age, sex, atrial fibrillation
(AF), diabetes, dyslipidaemia, potency or intensity of initial statin prescribed, treated hyper-
tension, prescription of corticosteroid and other lipid lowering medications, LDL-C level at
time of statin prescription and medication count. S3 Table provides the adjusted odds ratios,
with regression coefficients and constants presented in S4 Table.
The results of the model showed those with higher baseline levels of LDL-C, atrial fibrilla-
tion (in men only), diabetes, treated hypertension, increasing number of concurrent medica-
tions (in men only), high potency statins, and other lipid lowering drugs (in men only) were
less likely to have sub-optimal LDL-C reduction. Dyslipidaemias and corticosteroids were
associated with a higher likelihood of sub-optimal LDL-C reduction. The interaction terms
showed that when considered in relation to higher LDL-C levels, those on higher potency stat-
ins and had a diagnosis of dyslipidaemias were less likely to have sub-optimal response.
Validation of sub-optimal LDL-C statin response model
The discriminatory accuracy of the model in predicting sub-optimal LDL-C response per-
formed similarly in both UK cohorts (derivation AUROC 0.704, 95% CI 0.701–0.707, internal
validation AUROC 0.703 (95% CI 0.698–0.707) with a slightly lower performance in the HK
cohort (external validation AUC 0.677 (95% CI 0.675–0.680) (Table 2).
Calibrations plots (S1 Fig) show that the model was perfectly calibrated (slope = 1.0) for
UK populations by comparing the predicted and observed probability of sub-optimal statin
response across each tenth of predicted probabilities. For HK populations, the model under-
predicted risk with predicted probabilities consistently lower than observed probabilities
(slope = 0.86). An adjustment to the intercept term of the risk model in the HK population
would improve its calibration.
The sensitivity and specificity plots for the model are presented in S2 Fig. The optimum
trade-off occurred at 50% probability as determined by the maximum product index [20]
between sensitivity and specificity (shown at the intersection), and hence we classified individ-
uals with SR propensity >50% as “predicted sub-optimal response” and individuals�50% as
“predicted optimal response”. This binary classification resulted in a sensitivity of 64% (95%
CI 63.4% - 64.5%) and specificity of 64.9% (95% CI 64.3% - 65.5%).
Table 2. Model discrimination for sub-optimal LDL-C response to statins.
Statin Optimisation Model Sample Size AUROC (95% CI) Standard Error�
Derivation cohort: UK CPRD 128,248 0.704 (0.701–0.707) 0.002
Internal validation cohort: UK CPRD 54,965 0.703 (0.698–0.707) 0.002
External validation cohort: HK CDARS 170,904 0.677 (0.675–0.680) 0.001
�Jack-knife procedure to estimate standard errors.
AUROC (c-statistic): area under the receiver operating curve; CDARS: Clinical Data Analysis and Reporting System; CI: confidence interval; CPRD: Clinical Practice
Research Datalink; HK: Hong Kong; UK: United Kingdom.
https://doi.org/10.1371/journal.pone.0260839.t002
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Impact of adherence on model
Approximately 60% of the UK validation cohort (n = 33,491) had a discontinuation period
over two-years from starting statins. The statin adherence rate had explained 11% of the varia-
tion in the mean reduction in LDL-C (Pearson’s r = -0.33; R^2 = 0.108) and followed an
expected inverse association with both absolute and percentage mean reduction in LDL-C and
positive association with percentage patients achieving the targeted 40% reduction in LDL-C
from baseline (Table 3). The model performance ranged from AUROC of 0.637 (95% CI
0.606–0.670) for patients who had <20% adherence to an AUROC of 0.737 (95% CI 0.731–
0.742) in patients who had�80% adherence.
Stratifying groups by LDL-C statin response and CVD risk
Ten-year CVD risk recommended by ESC guidelines and two-year sub-optimal LDL-C reduc-
tion propensity was calculated for all patients in both cohorts from baseline risk factors (histo-
grams and distributions shown in S3 Fig). By jointly stratifying patients into “high” (> 5%) or
“low” (� 5%) CVD risk and “sub-optimal” (> 50%) or “optimal” (� 50%) LDL-C reduction,
four groups for statin response (SR) were created (shown in S4 Fig).
For the UK cohort, 45,684 patients (24.9%) were predicted to have optimal statin response
and low CVD risk (SR1), 64,997 patients (35.5%) were predicted to have sub-optimal statin
response and low CVD risk (SR2), 48,460 patients (26.5%) were predicted to have optimal
statin response and high CVD risk (SR3), and 24,072 patients (13.1%) were predicted to have
sub-optimal statin response and high CVD risk. For the HK cohort, 47,842 patients (27.9%)
were predicted to have optimal statin response and low CVD risk (SR1), 61,725 patients
(36.1%) were predicted to have sub-optimal statin response and low CVD risk (SR2), 43,514
patients (25.4%) were predicted to have optimal statin response and high CVD risk (SR3), and
17,823 patients (10.4%) were predicted to have sub-optimal statin response and high CVD
risk.
Characteristics of the groups for the UK patients are provided in S5 Table and HK patients
in S6 Table. For UK patients, classified as being at low CVD risk, patients predicted to have
sub-optimal compared to optimal response were more likely to be male (55.6% compared to
41.5%), less likely to be treated for hypertension (17.5% compared to 26.7%), with lower mean
LDL-C (133.4 mg/dL compared to 187.6 mg/dL), and more frequently initiated on a low
potency statin (34.2% compared to 5.4%). Following similar trends, UK patients classified as
being at high CVD risk, patients predicted to have sub-optimal response were more likely to
be male (64.6% compared to 52.6%), with lower mean LDL-C (123.2 mg/dL compared to
Table 3. Model performance stratified by statin adherence rates over 2-year follow-up in the United Kingdom CPRD validation cohort (n = 54,965).
Statin Adherence Rate
(%)�
Mean reduction in LDL-C
(SD), mg/dL
Percentage mean reduction in
LDL-C (%)




<20% -17.1 (36.7) -19.1% 9.9% 0.637 (0.606–0.670)
20-< 40% -30.6 (41.6) -35.8% 22.2% 0.633 (0.613–0.653)
40-< 60% -44.2 (61.3) -53.7% 35.0% 0.642 (0.627–0.658)
60-< 80% -54.6 (40.5) -69.9% 48.2% 0.672 (0.661–0.684)
�80% -65.7 (76.7) -81.6% 58.2% 0.737 (0.731–0.742)
� Proxy marker for adherence by medication possession count over two-year follow-up from each patient’s prescribing record. Estimation of start/stop dates
representing discontinuation periods are based on statin pack size and prescribed daily dosage.
AUROC: area under the receiver operating curve; CI: confidence interval; CPRD: Clinical Practice Research Datalink; LDL-C: low-density lipoprotein cholesterol; SD:
standard deviation.
https://doi.org/10.1371/journal.pone.0260839.t003
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174.9 mg/dL), less likely to be treated for hypertension (27.4% compared to 35.4%), and were
much more likely to initiated on a low potency statin (52.8% compared to 12.2%).
In HK patients, SR groups were also significantly different across groups but with some dif-
ferences compared to UK patients. In HK patients classified as being at low CVD risk, patients
predicted to have sub-optimal compared to optimal response were more likely to be male
(53.3% compared to 32.1%), lower mean LDL-C (207.4 mg/dL compared to 259.8 mg/dL), less
likely to be diabetic (14.2% compared to 23.4%), and less likely to be treated for hypertension
(7.1% compared to 14.5%). Similarly, HK patients predicted to have sub-optimal compared to
optimal response in high CVD risk groups also were more likely to be male (70.9% compared
to 47.6%), have lower mean LDL-C (113.6 mg/dL compared to 166.7 mg/dL), less likely to be
diabetic (11.0% compare to 24.2%) or treated for hypertension (10.1% compared to 22.0%).
Potency of statin prescribing remained stable in HK patients across all groups, favouring lower
dosage statins compared to UK patients. Similar to UK patients, HK patients in high CVD risk
groups were generally older, with higher numbers of men, medication count, and smokers.
Two-year follow-up of LDL-C reduction
Baseline and 2-year follow-up LDL-C levels after statin initiation for UK and HK patients are
shown in Fig 3. Higher baseline LDL-C levels resulted in more prominent reductions in
LDL-C over two years. In UK patients, low and high CVD risk groups, respectively, achieved
40.5% and 41.9% reduction in mean LDL-C in predicted optimal response groups whereas the
mean reduction in LDL-C in predicted sub-optimal responders was only 26.8% and 28.6%. In
HK patients, low and high CVD risk groups, respectively, achieved 35.0% and 36.7% reduction
in mean LDL-C in predicted optimal response groups whereas the mean reduction in LDL-C
in predicted sub-optimal responders was only 20.5% and 22.4%. Overall, variability of the
LDL-C response in patients in both UK and HK cohorts remained quite high ranging from
60% reduction in LDL-C to increase of 50% in LDL-C after two years of treatment (S5 Fig).
Fig 3.
https://doi.org/10.1371/journal.pone.0260839.g003
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Long-term follow-up MACE outcomes
Incidence rates (per 1000 person-years) over 10-years for MACE increased significantly across
groups (S7 Table). Increasing incidence across SR groups followed similar trends for all-cause
mortality, CHD, stroke/TIA, PVD and CVD death for both cohorts. CHD was the most com-
mon MACE event to occur during follow-up. Cumulative incidence graphs for 10-year MACE
are displayed in Fig 4. In high CVD risk groups, the absolute difference in MACE cumulative
event rate at the end of 10-year follow-up was 8% greater in UK patients and 11% greater in
HK patients between predicted sub-optimal statin responders (SR4) and predicted optimal
statin responders (SR3). Even in low-risk CVD groups, the absolute difference in MACE
cumulative event rate at the end of 10-year follow-up was 5% greater in UK patients and 7%
greater in HK patients between predicted sub-optimal statin responders (SR2) and predicted
optimal statin responders (SR1).
Ten-year models (Table 4) showed that predicted sub-optimal SR in patients with low
CVD risk (comparing SR2 to SR1), resulted in hazard ratios for MACE of 1.39 (95% CI 1.35–
1.43, p< 0.001) for UK patients and 1.14 (95% CI 1.11–1.17, p< 0.001) for HK patients. Pre-
dicted sub-optimal SR in patients with high CVD risk (comparing SR4 to SR3) resulted in haz-
ard ratios for MACE of 1.36 (95% CI 1.32–1.40, p< 0.001) for UK patients and 1.25 (95% CI
1.21–1.28, p < 0.001) for HK patients. In UK patients, the risk of constituent MACE outcomes
increased significantly in patients predicted to be sub-optimal responders for CHD, stroke/
TIA, and PVD in both high and low CVD risk groups. There was an increased risk of all-cause
mortality in UK patients in high CVD risk groups but not in low CVD risk groups. There was
no significant difference in CVD death in UK patients. In HK patients, risk of CHD was
increased in both low and high CVD risk groups in predicted sub-optimal SR groups. Stroke/
TIA and PVD was, however, only increased for sub-optimal SR in high CVD risk groups. Sub-
optimal SR groups had significantly lower risks of CVD death and all-cause mortality in
patients with low CVD risk (HR<1.0), which can be explained by this group being younger
and healthier.
Discussion
This international study in two countries has identified clinical characteristics of patients that
predict variation in LDL-C in response to statin therapy commenced for primary prevention
of CVD. We have found that irrespective of their baseline CVD risk, patients with poorer
LDL-C response experience much greater rates and risk of adverse cardiovascular outcomes
than those likely to achieve target reductions in LDL-C. Groups who have low predicted likeli-
hood to achieve LDL-C treatment targets will experience overall 5–10 more CVD events per
1000 person-years with low baseline CVD risk. The effect is even greater in populations with
high baseline CVD risk, with 19–20 more CVD events per 1000-years, compared to population
groups with predicted optimal response.
An individual’s response to statins should be considered alongside cardiovascular risk
assessment to enhance cholesterol treatment strategies and to inform shared decision-making
with patients as part of primary prevention of CVD. To our knowledge, this is the first study to
demonstrate sub-optimal LDL-C response to statins can be reliably predicted. Our statin
response model uses patient characteristics that are routinely available in electronic health rec-
ords and was robust in both validation cohorts. Considering the effects of adherence, we
showed the model predicts LDL-C response when patients are more compliant to their medi-
cines, suggesting there is biological variation in treatment response. In less compliant individ-
uals, expectedly, there is less certainty in predicting LDL-C response.
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Statin response was associated with age, dyslipidaemias, potency of prescribed statin, base-
line LDL-C level and the use of other medications (other lipid therapies and corticosteroids).
These factors have been previously found to be associated with variability in LDL-C response
[21, 22]. Corticosteroids are usually prescribed to patients with conditions associated with
higher levels of inflammation and thus interact with the effectiveness of statins. Patients in
Fig 4.
https://doi.org/10.1371/journal.pone.0260839.g004
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both cohorts who were less likely to achieve targeted LDL-C reduction were also more likely to
have lower baseline LDL-C levels and be initiated on low potency statins. However, there was
greater use of more potent statins in the UK cohort compared to the HK cohort, while greater
use of other non-statin lipid lowering drugs in the HK cohort compared to the UK cohort.
Recent updates to cholesterol guidelines have broadened the population of individuals eligi-
ble for statins for primary prevention [3, 10, 11, 17]. For example, the UK NICE guideline [3]
now suggest statin therapy be considered for individuals who have a cardiovascular risk
score > 10%, which has been reduced from a previous threshold of> 20%. In the current
study, over half of patients who initiated statins had a sub-optimal LDL-C response in both
HK and UK. This would equate to about 6.1 million of the estimated 12 million adults aged
30–84 in the UK who could be eligible for statins, for primary prevention [23].
Other factors, such as physical activity, diet and statin or treatment side-effects (which are
less reliably recorded) should clearly also be considerations alongside statin alternatives to
achieve shared clinical decision making with patients for appropriate cholesterol management.
However, identifying patients likely to have sub-optimal LDL-C response to statins could
enable clinicians to be more aggressive in cholesterol management by identifying those who
need closer monitoring, or initiated on higher statin doses, given in combination with ezeti-
mibe [24]. Recent evidence suggests that reduction in cardiovascular events is significant even
to ultra-low levels of LDL-C less than 0.2 mmol/L (7.7 mg/dL) [25]. Our study shows that
many patients are initiated on low dose statins in the predicted sub-optimal groups suggesting
many clinicians may not be aware of the clinical benefits of a stronger treatment regime even
in those with lower baseline levels of LDL-C with high risk of CVD.
Medications that aim to reduce LDL-C such as PCSK9 inhibitors and Ezetimibe [26, 27] are
presently indicated for both primary and secondary prevention of CVD. When taken in combina-
tion with statin and diet therapies, additional reduction in LDL-C levels have been shown in trials.
The strengths of this study include its large sample size, long-term follow-up, from general
patient populations in two countries, derived from high quality electronic patient health
Table 4. Hazard ratios (95% confidence intervals) for 10-year major adverse cardiovascular events and all-cause mortality for predicted statin response and cardio-
vascular risk groups.
Group MACE All-Cause Mortality Specific CVD Outcomes
CHD Stroke/TIA PVD CVD Death
United Kingdom CPRD cohort 10-year outcomes
Number of events, N (%) 40,928 (22.3) 13,199 (7.2) 27,257 (14.9) 7,017 (3.8) 4,835 (2.6) 1,819 (1.0)
SR2: Predicted sub-optimal statin response
& low CVD risk†
1.39 (1.35–1.43) � 0.94 (0.88–1.01) 1.45 (1.40–1.50) � 1.30 (1.21–1.41) � 1.27 (1.16–1.38) � 0.86 (0.72–1.03)
SR4: Predicted sub-optimal statin response
& high CVD risk‡
1.36 (1.32–1.40) � 1.10 (1.06–1.15) � 1.47 (1.42–1.52) � 1.24 (1.16–1.32) � 1.18 (1.09–1.28) � 1.10 (0.98–1.23)
Hong Kong CDARS cohort 10-year outcomes
Number of events, N (%) 37,777 (22.1) 28,321 (16.5) 17,371 (10.2) 14,321 (8.4) 1,554 (0.9) 4,531 (2.7)
SR2: Predicted sub-optimal statin response
& low CVD risk†
1.14 (1.11–1.17) � 0.78 (0.75–0.82) � 1.51 (1.45–1.57) � 1.00 (0.95–1.04) 0.95 (0.83–1.09) 0.73 (0.66–0.81) �
SR4: Predicted sub-optimal statin response
& high CVD risk‡
1.25 (1.21–1.28) � 1.06 (1.03–1.09) � 1.69 (1.60–1.78) � 1.10 (1.04–1.16) � 1.17 (1.00–1.37) � 0.97 (0.90–1.05)
�p <0.05.
†reference group: SR1-predicted optimal statin response & low CVD risk.
‡reference group: SR3-predicted optimal statin response & high CVD risk.
CDARS: Clinical Data Analysis and Reporting System; CHD: coronary heart disease; CPRD: Clinical Practice Research Datalink; CVD: cardiovascular disease; MACE:
major adverse cardiovascular event; PVD: peripheral vascular disease; TIA: transient ischemic attack.
https://doi.org/10.1371/journal.pone.0260839.t004
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records. Data linkages to hospital records and death registries enhanced the quality of outcome
ascertainment for the cohorts of patients derived from these databases. Although the model
was developed using a UK cohort, the applicability of the model in the ethnically different HK
cohort, enhances external validity and generalisability of more aggressive lipid management
across both Western and Asian populations. By adopting an open cohort design and account-
ing for statin type and intensity, the predicted statin response and event rates across time peri-
ods reflect real-world changes in practice over time. Both populations have experienced
prescribing trends towards stronger statin intensity over time [7, 28].
Some limitations of this study are recognized. Although the proxy for statin adherence
explained a third of the variation in LDL-C response, prescribing records cannot confirm
whether a patient actually takes their medication, which is a shared limitation of all observa-
tional studies and trials. Moreover, patients who are on cardioprotective therapies are likely to
be on other medications other than statins and are more likely to discontinue multiple thera-
pies, which has also been shown to influence the mortality outcomes [29]. In common with
other large population studies using routinely collected data, this limitation together with oth-
ers including ascertainment and information bias, potential bias due to missing data and
unmeasured confounding is acknowledged. Newer medications such as PCSK9 are not yet
indicated for primary prevention, hence no data was available to assess its effect on cholesterol
response. We used the ESC guidelines to stratify CVD risk due to its simplicity, accessibility to
the published risk equations, and being recommended by ESC and HK guideline committees
as acceptable for use in both the UK and HK. We acknowledge that different national guide-
lines may recommend use of other CVD risk equations. Finally, we did not consider the effects
of medication switching during follow-up. Future analysis could consider modelling the effects
of time-varying exposure periods to account for any changes of dosing.
Conclusions
Predicted sub-optimal LDL-C lowering response to statins consistently resulted in higher rates
of MACE. To enhance cholesterol management for primary prevention of CVD, clinicians
should consider a patient’s likely response to statins as a component of CVD risk assessment.
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